Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $12.27 in the prior trading day, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) closed at $12.14, down -1.10%. In other words, the price has decreased by -$1.10 from its previous closing price. On the day, 1.68 million shares were traded. AUPH stock price reached its highest trading level at $12.46 during the session, while it also had its lowest trading level at $12.125.
Ratios:
Our goal is to gain a better understanding of AUPH by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.07 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.31. For the most recent quarter (mrq), Quick Ratio is recorded 4.63 and its Current Ratio is at 5.23. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.19.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’25 when TANG KEVIN bought 1,000,000 shares for $10.12 per share. The transaction valued at 10,120,000 led to the insider holds 11,029,500 shares of the business.
TANG KEVIN bought 200,000 shares of AUPH for $2,336,000 on Aug 05 ’25. The Director now owns 11,329,500 shares after completing the transaction at $11.68 per share. On Aug 04 ’25, another insider, TANG KEVIN, who serves as the Director of the company, bought 100,000 shares for $11.34 each. As a result, the insider paid 1,134,000 and bolstered with 11,129,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 1597330048 and an Enterprise Value of 1364109568. As of this moment, Aurinia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.38, and their Forward P/E ratio for the next fiscal year is 15.93. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.14 while its Price-to-Book (P/B) ratio in mrq is 4.80. Its current Enterprise Value per Revenue stands at 5.244 whereas that against EBITDA is 16.518.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.27, which has changed by 0.8031204 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $12.53, while it has fallen to a 52-week low of $6.42. The 50-Day Moving Average of the stock is 26.77%, while the 200-Day Moving Average is calculated to be 41.40%.
Shares Statistics:
The stock has traded on average 2.02M shares per day over the past 3-months and 1992170 shares per day over the last 10 days, according to various share statistics. A total of 132.67M shares are outstanding, with a floating share count of 118.78M. Insiders hold about 9.76% of the company’s shares, while institutions hold 43.74% stake in the company. Shares short for AUPH as of 1753920000 were 9156638 with a Short Ratio of 4.53, compared to 1751241600 on 10015540. Therefore, it implies a Short% of Shares Outstanding of 9156638 and a Short% of Float of 7.62.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 6.0 analysts currently analyzing and rating the stock of Aurinia Pharmaceuticals Inc (AUPH).The consensus estimate for the next quarter is $0.15, with high estimates of $0.22 and low estimates of $0.07.
Analysts are recommending an EPS of between $0.81 and $0.5 for the fiscal current year, implying an average EPS of $0.65. EPS for the following year is $0.76, with 6.0 analysts recommending between $1.22 and $0.57.
Revenue Estimates
7 analysts predict $67.33M in revenue for the current quarter. It ranges from a high estimate of $69.11M to a low estimate of $65.03M. As of the current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $67.77MFor the next quarter, 7 analysts are estimating revenue of $69.93M. There is a high estimate of $72.3M for the next quarter, whereas the lowest estimate is $66.5M.
A total of 7 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $273.2M, while the lowest revenue estimate was $265M, resulting in an average revenue estimate of $269.76M. In the same quarter a year ago, actual revenue was $235.13MBased on 7 analysts’ estimates, the company’s revenue will be $309.87M in the next fiscal year. The high estimate is $356.92M and the low estimate is $284.45M.
